CN114929714B - 用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽 - Google Patents

用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽 Download PDF

Info

Publication number
CN114929714B
CN114929714B CN202080091936.3A CN202080091936A CN114929714B CN 114929714 B CN114929714 B CN 114929714B CN 202080091936 A CN202080091936 A CN 202080091936A CN 114929714 B CN114929714 B CN 114929714B
Authority
CN
China
Prior art keywords
present disclosure
compound
pharmaceutically acceptable
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080091936.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929714A (zh
Inventor
汪涛
P·M·斯科拉
张钟兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN114929714A publication Critical patent/CN114929714A/zh
Application granted granted Critical
Publication of CN114929714B publication Critical patent/CN114929714B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202080091936.3A 2020-01-06 2020-11-19 用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽 Active CN114929714B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957373P 2020-01-06 2020-01-06
US62/957,373 2020-01-06
PCT/US2020/061172 WO2021141682A1 (en) 2020-01-06 2020-11-19 Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases

Publications (2)

Publication Number Publication Date
CN114929714A CN114929714A (zh) 2022-08-19
CN114929714B true CN114929714B (zh) 2024-05-31

Family

ID=73835779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091936.3A Active CN114929714B (zh) 2020-01-06 2020-11-19 用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽

Country Status (7)

Country Link
US (1) US20230063238A1 (https=)
EP (1) EP4087849B1 (https=)
JP (1) JP7550864B2 (https=)
KR (1) KR20220122751A (https=)
CN (1) CN114929714B (https=)
ES (1) ES2971704T3 (https=)
WO (1) WO2021141682A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US20230374073A1 (en) * 2020-10-08 2023-11-23 Bristol-Myers Squibb Company Dimeric milla immunomodulators
KR20230084211A (ko) * 2020-10-09 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
JP2024544009A (ja) * 2021-12-03 2024-11-26 ブリストル－マイヤーズ スクイブ カンパニー 大員環免疫調節剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999536A (zh) * 2014-09-11 2017-08-01 百时美施贵宝公司 Pd‑1/pd‑l1及cd80(b7‑1)/pd‑l1蛋白质/蛋白质相互作用的大环抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999536A (zh) * 2014-09-11 2017-08-01 百时美施贵宝公司 Pd‑1/pd‑l1及cd80(b7‑1)/pd‑l1蛋白质/蛋白质相互作用的大环抑制剂

Also Published As

Publication number Publication date
WO2021141682A1 (en) 2021-07-15
EP4087849B1 (en) 2023-12-27
JP7550864B2 (ja) 2024-09-13
JP2023510736A (ja) 2023-03-15
KR20220122751A (ko) 2022-09-02
CN114929714A (zh) 2022-08-19
ES2971704T3 (es) 2024-06-06
US20230063238A1 (en) 2023-03-02
EP4087849A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
CN114929714B (zh) 用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽
EP4087857B1 (en) Immunomodulators
CN114641480A (zh) 作为pd-l1抑制剂和免疫调节剂用于治疗癌症和感染性疾病的大环肽
CN115485288A (zh) 免疫调节剂
CN114555627A (zh) 免疫调节剂
EP4146670A1 (en) Immunomodulators
EP4225774B1 (en) Macrocyclic immunomodulators
EP4126902B1 (en) Immunomodulators
EP4225775B1 (en) Dimeric milla immunomodulators
CN116322735A (zh) 大环肽硼酸盐免疫调节剂
CN117157307A (zh) 环肽免疫调节剂
EP4323380A2 (en) Cyclic peptide immunomodulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant